RecruitingPhase 3NCT06290128
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- Riliprubart(drug)
- Enrollment
- 140 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Alabama Neurology Associates- Site Number : 8400019, Homewood, Alabama, United States
- USC Norris Comprehensive Cancer Center- Site Number : 8400002, Los Angeles, California, United States
- University of California Irvine - Manchester Pavilion- Site Number : 8400007, Orange, California, United States
- Yale University School of Medicine- Site Number : 8400018, New Haven, Connecticut, United States
- NorthShore University Health System - Glenbrook Hospital- Site Number : 8400024, Glenview, Illinois, United States
- University of Kansas Medical Center- Site Number : 8400010, Kansas City, Kansas, United States
- NeuroMedical Clinic of Central Louisiana- Site Number : 8400031, Alexandria, Louisiana, United States
- Ochsner Medical Center - Jefferson Highway- Site Number : 8400030, New Orleans, Louisiana, United States
- Johns Hopkins Hospital- Site Number : 8400015, Baltimore, Maryland, United States
- Massachusetts General Hospital- Site Number : 8400009, Boston, Massachusetts, United States
- Henry Ford Hospital- Site Number : 8400025, Detroit, Michigan, United States
- Michigan State University- Site Number : 8400038, East Lansing, Michigan, United States
- Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037, St Louis, Missouri, United States
- Hospital for Special Surgery- Site Number : 8400041, New York, New York, United States
- Columbia University Irving Medical Center- Site Number : 8400003, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06290128 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →